NeuroSense Therapeutics Ltd. Cash Flows From Used In Financing Activities
NeuroSense Therapeutics Ltd. (NRSN) reported Cash Flows From Used In Financing Activities of $3.90 million for the 12-month period ending 2023-12-31, per its 20-F filed 2024-04-04.
Discontinued › Cash Flow › Financing Activities
ifrs-full:CashFlowsFromUsedInFinancingActivities · last filed 2024-04-04
| Period end | Cash Flows From Used In Financing Activities 6 month | Cash Flows From Used In Financing Activities 12 month |
|---|---|---|
| 2023-12-31 | $3.90M 20-F · filed 2024-04-04 | |
| 2023-06-30 | $4.10M 6-K · filed 2023-08-16 | |
| 2022-12-31 | $3.69M 20-F · filed 2024-04-04 | |
| 2022-06-30 | $3.71M 6-K · filed 2023-08-16 | |
| 2021-12-31 | $11.90M 20-F · filed 2024-04-04 | |
| 2021-06-30 | $700.00K 6-K/A · filed 2023-01-19 | |
| 2020-12-31 | $508.00K 20-F · filed 2023-03-22 | |
| 2019-12-31 | $1.42M 20-F · filed 2022-04-14 |